India's Jubilant Pharmova gains as US FDA closes inspection without urging action
** Shares of Jubilant Pharmova JUBA.NS jump 2% to 882.30 rupees ** U.S. FDA completes inspection of drugmaker's manufacturing site in Maryland, classifies it as "voluntary action indicated" ** VAI indicates the agency is not prepared to take or recommend any administrative or regulatory action, per the FDA website ** Stock down 21% this year after doubling in 2024 (Reporting by Nandan Mandayam in Bengaluru) ((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))
Recent news on Jubilant Pharmova
See all newsBrief: Jubilant Pharmova Sept-Quarter Consol Net Profit 312 Million Rupees
Brief: Jubilant Pharmova Says Jubilant Therapeutics Announces Oral Presentation Of Preliminary Phase 1 Clinical Data For JBI-802
India New Issue-Jubilant Pharmova to issue 3-year bonds, bankers say
India's Jubilant Pharmova eyes $150 mln through rupee debt sale, bankers say
Brief: Jubilant Pharmova To Consider Raising Of Funds Through Issuance Of Non- Convertible Debentures